Gaikwad Sanket, Jalgaonkar Sharmila, Tripathi Raakhi
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Nagpur, IND.
Department of Pharmacology and Therapeutics, Seth Gordhandas Sunderdas (GS) Medical College and King Edward Memorial (KEM) Hospital, Mumbai, IND.
Cureus. 2025 Jun 16;17(6):e86175. doi: 10.7759/cureus.86175. eCollection 2025 Jun.
Ulcerative colitis (UC) is the most common form of inflammatory bowel disease worldwide. It is a chronic, debilitating condition that affects an individual throughout life. Patients of UC tend to have a reduced quality of life from continuous disease activity and significant complications, with a risk of developing colon cancer later in life. The current therapy does not aim to cure the disease but focuses on suppressing symptoms and improving quality of life. Despite great advances in the modern management of UC with the introduction of new effective drugs, adoption of stricter endpoints, and use of better treatment strategies, there remain many unmet needs. S-Adenosyl-L-methionine (SAMe) is available as a dietary supplement that exerts anti-inflammatory and antioxidant effects. It is also approved for add-on use in depression, osteoarthritis, and liver diseases. The present study examined the gastroprotective effects of SAMe in an animal model that simulates UC.
The aim of this study was to investigate the protective effects of SAMe in an animal model of chronic colitis. After Institutional Animal Ethics Committee (IAEC) approval (IAEC/03/2022), 32 Swiss albino mice were divided into four groups with eight animals per group as the normal control (NC), disease control (DC), positive control (SLZ), and test group (SAMe). All study groups except the NC group (given normal saline) were administered 2% dextran sulfate sodium (DSS) in drinking water for seven days and only drinking water for the next seven days. This cycle of 14 days was repeated three times to induce chronic colitis. The positive control group was given sulfasalazine 100 mg/kg/day, and the test group was given SAMe 200 mg/kg/day from day 1 to day 42. The Disease Activity Index (DAI) was assessed every seven days. On day 42, all animals were sacrificed, and the colon was isolated to assess the weight-by-length ratio, macroscopic grading, histopathological scoring, and biomarkers: TNF-α and glutathione (GSH). The colon weight-by-length ratio was assessed and analyzed using one-way ANOVA. DAI, colitis macroscopy, and histopathology score were assessed and analyzed using the Kruskal-Wallis test. A value of p < 0.05 was considered to be statistically significant.
It was observed that SAMe significantly reduced the colon weight-by-length ratio, colitis macroscopy grading, DAI, histopathology score, and TNF-α level as compared to the DC group, which indicated its anti-inflammatory effect. SAMe also significantly increased the GSH level as compared to the DC group, which indicated its antioxidant effect. Also, it was observed that the effects of SAMe were comparable to the positive control sulfasalazine.
According to our study's findings, SAMe exerts a gastroprotective effect comparable to that of sulfasalazine, as evidenced by the reduction in DAI, colon weight-by-length ratio, macroscopy grading, histopathology score, and TNF-α level. The increase in the GSH levels by SAMe signifies a decrease in oxidative stress, which may be responsible for the gastroprotective effect.
溃疡性结肠炎(UC)是全球最常见的炎症性肠病形式。它是一种慢性、使人衰弱的疾病,会影响个体一生。UC患者由于疾病持续活动和严重并发症,生活质量往往会下降,且后期有患结肠癌的风险。目前的治疗方法并非旨在治愈该疾病,而是侧重于抑制症状和提高生活质量。尽管随着新型有效药物的引入、更严格终点的采用以及更好治疗策略的使用,UC的现代管理取得了巨大进展,但仍存在许多未满足的需求。S-腺苷-L-甲硫氨酸(SAMe)作为一种膳食补充剂,具有抗炎和抗氧化作用。它也被批准用于抑郁症、骨关节炎和肝脏疾病的辅助治疗。本研究在模拟UC的动物模型中研究了SAMe的胃保护作用。
本研究的目的是在慢性结肠炎动物模型中研究SAMe的保护作用。经机构动物伦理委员会(IAEC)批准(IAEC/03/2022)后,将32只瑞士白化小鼠分为四组,每组8只,分别作为正常对照组(NC)、疾病对照组(DC)、阳性对照组(SLZ)和试验组(SAMe)。除NC组(给予生理盐水)外,所有研究组均在饮用水中给予2%硫酸葡聚糖钠(DSS)7天,接下来7天仅给予饮用水。这个14天的周期重复三次以诱导慢性结肠炎。阳性对照组从第1天到第42天给予柳氮磺胺吡啶100 mg/kg/天,试验组给予SAMe 200 mg/kg/天。每7天评估疾病活动指数(DAI)。在第42天,处死所有动物,分离结肠以评估长度重量比、宏观分级、组织病理学评分和生物标志物:肿瘤坏死因子-α(TNF-α)和谷胱甘肽(GSH)。使用单因素方差分析评估和分析结肠长度重量比。使用Kruskal-Wallis检验评估和分析DAI、结肠炎宏观检查和组织病理学评分。p值<0.05被认为具有统计学意义。
观察到与DC组相比,SAMe显著降低了结肠长度重量比、结肠炎宏观分级、DAI、组织病理学评分和TNF-α水平,这表明其具有抗炎作用。与DC组相比,SAMe还显著提高了GSH水平,这表明其具有抗氧化作用。此外,观察到SAMe的作用与阳性对照柳氮磺胺吡啶相当。
根据我们研究的结果,SAMe发挥了与柳氮磺胺吡啶相当的胃保护作用,DAI、结肠长度重量比、宏观分级、组织病理学评分和TNF-α水平的降低证明了这一点。SAMe使GSH水平升高表明氧化应激降低,这可能是胃保护作用的原因。